Receptor affinity of neurotensin message segment immobilized on liposome

Preparation of functional liposomes with peptide ligands and their binding to cell membranes

Two novel lipopeptides, which have the peptide ligands [alpha-melanocyte stimulating hormone (alpha-MSH)] sequence and repeated [Gly-Arg-Gly-Asp-Se (GRGDS) sequence], are designed, synthesized by the solid-phase method, and introduced into liposome membranes by the freeze-thaw method. These liposomes bearing the peptide ligands on their surface are expected to bind to cell membranes. We have confirmed that the lipopeptides are introduced into liposome membranes almost quantitatively, while such a high degree of incorporation has not been accomplished in conventional methods. In this respect, the present method is superior to prepare surface-modified liposomes that are applicable to drug carriers and so on. We have also confirmed by using immunoelectron microscopy that the peptide ligands are actually located in an aqueous phase. It has been shown by flow cytometry that the liposome bearing alpha-MSH peptide ligand binds to B16 cells and the liposome bearing the repeated GRGDS sequence binds to NIH3T3 cells.

Enkephalin-cell interactions

Enkephalin analogs for multivalent ligand systems, bivalent enkephalins, multivalent enkephalins on polymers, multivalent ligands on vesicles, simultaneous activation of two different receptor systems, and cell interactions of enkephalin/polypeptide conjugates are described. Multivalent ligand systems can trigger receptor-receptor interactions and are considered to possess interesting possibilities in terms of enhanced potency, reduction of side effects, and a new biological activity.

Simultaneous activation of two different receptor systems by enkephalin/neurotensin conjugates having spacer chains of various lengths

Bivalent ligands composed of enkephalin and neurotensin were prepared and their action in the receptor-receptor interaction was studied with the neuroblastoma cell, NG108-15. Enkephalin was connected via oligosarcosine spacer chain to the N-terminus of neurotensin(8-13). The bivalent ligand stimulated the cGMP production more than plain neurotensin. The affinity of the bivalent ligands for the neurotensin receptor changed with varying lengths of the spacer chain. When the spacer chain was an octamer or a dodecamer of sarcosine, the receptor affinity of those bivalent ligands was higher than neurotensin(1-13), and significantly decreased in the presence of excess amount of enkephalin. These results suggest that the bivalent ligands bind to opioid receptor and neurotensin receptor simultaneously, leading to receptor-receptor interaction. On the other hand, some bivalent ligands, especially that without a spacer chain seemed to bind to the neurotensin receptor by the help of the enkephalin part interacting with a receptor exosite.